Published in Cancer Res on March 01, 2007
Probing the probes: fitness factors for small molecule tools. Chem Biol (2010) 2.08
Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel. Cancer Res (2008) 1.74
Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells. Cancer Res (2009) 1.34
A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. Invest New Drugs (2010) 1.30
New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential. Drug Resist Updat (2009) 1.27
The hemopexin domain of MMP3 is responsible for mammary epithelial invasion and morphogenesis through extracellular interaction with HSP90β. Genes Dev (2013) 1.08
Different poses for ligand and chaperone in inhibitor-bound Hsp90 and GRP94: implications for paralog-specific drug design. J Mol Biol (2009) 1.06
Modulation of melanoma cell phospholipid metabolism in response to heat shock protein 90 inhibition. Oncotarget (2010) 0.98
Antimelanoma activity of the redox dye DCPIP (2,6-dichlorophenolindophenol) is antagonized by NQO1. Biochem Pharmacol (2009) 0.91
Mode of cell death induced by the HSP90 inhibitor 17-AAG (tanespimycin) is dependent on the expression of pro-apoptotic BAX. Oncotarget (2013) 0.90
Measurement of nanomolar dissociation constants by titration calorimetry and thermal shift assay - radicicol binding to Hsp90 and ethoxzolamide binding to CAII. Int J Mol Sci (2009) 0.87
Inhibition of gastric tumor growth by a novel Hsp90 inhibitor. Biochem Pharmacol (2013) 0.86
Natural Product Inspired N-Terminal Hsp90 Inhibitors: From Bench to Bedside? Med Res Rev (2015) 0.84
Thermodynamics of aryl-dihydroxyphenyl-thiadiazole binding to human Hsp90. PLoS One (2012) 0.81
Co-crystalization and in vitro biological characterization of 5-aryl-4-(5-substituted-2-4-dihydroxyphenyl)-1,2,3-thiadiazole Hsp90 inhibitors. PLoS One (2012) 0.80
Proteome alteration induced by hTERT transfection of human fibroblast cells. Proteome Sci (2008) 0.79
Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance Spectroscopy. BMC Res Notes (2012) 0.79
N-benzyl-5-phenyl-1H-pyrazole-3-carboxamide promotes vascular endothelial cell angiogenesis and migration in the absence of serum and FGF-2. Acta Pharmacol Sin (2011) 0.77
Heat shock protein-90 inhibitors enhance antigen expression on melanomas and increase T cell recognition of tumor cells. PLoS One (2014) 0.75
Synthesis, characterization, and pharmacological evaluation of novel azolo- and azinothiazinones containing 2,4-dihydroxyphenyl substituent as anticancer agents. Monatsh Chem (2015) 0.75
A cell-based screen for inhibitors of protein folding and degradation. Cell Stress Chaperones (2010) 0.75
A small molecule screen reveals that HSP90β promotes the conversion of iPSC-derived endoderm to a hepatic fate and regulates HNF4A turnover. Development (2017) 0.75
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell (2004) 19.51
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell (2010) 17.48
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol (2008) 10.91
Melanoma biology and new targeted therapy. Nature (2007) 10.71
The RAF proteins take centre stage. Nat Rev Mol Cell Biol (2004) 8.04
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93
Structural insights into mRNA recognition from a PIWI domain-siRNA guide complex. Nature (2005) 6.23
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol (2010) 6.04
Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu Rev Biochem (2006) 5.82
Crystal structure of an Hsp90-nucleotide-p23/Sba1 closed chaperone complex. Nature (2006) 5.42
Guilty as charged: B-RAF is a human oncogene. Cancer Cell (2004) 4.97
Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell (2009) 4.76
GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem Biol (2003) 4.60
V599EB-RAF is an oncogene in melanocytes. Cancer Res (2004) 4.49
In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res (2006) 4.29
Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol Cell (2005) 4.24
Chaperoned ubiquitylation--crystal structures of the CHIP U box E3 ubiquitin ligase and a CHIP-Ubc13-Uev1a complex. Mol Cell (2005) 4.05
Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A. Cancer Cell (2011) 4.02
Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res (2012) 4.01
Gatekeeper mutations mediate resistance to BRAF-targeted therapies. Sci Transl Med (2010) 3.98
Activation of the ATPase activity of hsp90 by the stress-regulated cochaperone aha1. Mol Cell (2002) 3.89
B-RAF is a therapeutic target in melanoma. Oncogene (2004) 3.61
Crystal structure of a PIWI protein suggests mechanisms for siRNA recognition and slicer activity. EMBO J (2004) 3.57
Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol (2005) 3.42
Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol (2008) 3.41
The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J (2008) 3.33
Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol (2012) 3.10
Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res (2007) 3.09
Structural and functional analysis of the middle segment of hsp90: implications for ATP hydrolysis and client protein and cochaperone interactions. Mol Cell (2003) 2.83
ROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma. Cancer Cell (2011) 2.77
NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res (2008) 2.76
Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation. BMC Biol (2012) 2.70
Structure of an Hsp90-Cdc37-Cdk4 complex. Mol Cell (2006) 2.62
Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia. Cancer Cell (2011) 2.57
Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov (2012) 2.56
Inhibitors of the HSP90 molecular chaperone: current status. Adv Cancer Res (2006) 2.55
HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther (2002) 2.53
Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell (2008) 2.49
Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther (2009) 2.43
Identification of direct transcriptional targets of (V600E)BRAF/MEK signalling in melanoma. Pigment Cell Melanoma Res (2009) 2.42
New insight into BRAF mutations in cancer. Curr Opin Genet Dev (2007) 2.40
Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells. Blood (2007) 2.38
The Mechanism of Hsp90 regulation by the protein kinase-specific cochaperone p50(cdc37). Cell (2004) 2.36
Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res (2005) 2.34
Structural basis for recruitment of glycogen synthase kinase 3beta to the axin-APC scaffold complex. EMBO J (2003) 2.33
Structural basis for the requirement of additional factors for MLL1 SET domain activity and recognition of epigenetic marks. Mol Cell (2009) 2.32
Regulation of Hsp90 ATPase activity by the co-chaperone Cdc37p/p50cdc37. J Biol Chem (2002) 2.32
Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res (2010) 2.30
New approaches to molecular cancer therapeutics. Nat Chem Biol (2006) 2.28
Enhancement of the seed-target recognition step in RNA silencing by a PIWI/MID domain protein. Mol Cell (2009) 2.27
Structural basis for recruitment of translesion DNA polymerase Pol IV/DinB to the beta-clamp. EMBO J (2003) 2.25
Swe1Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone function. Mol Cell (2010) 2.24
Inhibitors of the heat shock response: biology and pharmacology. FEBS Lett (2007) 2.21
ERK-MAPK signaling opposes Rho-kinase to promote endothelial cell survival and sprouting during angiogenesis. Cancer Cell (2006) 2.20
Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. PLoS One (2008) 2.15
Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer (2006) 2.11
A selective PIKfyve inhibitor blocks PtdIns(3,5)P(2) production and disrupts endomembrane transport and retroviral budding. EMBO Rep (2008) 2.09
A useful approach to identify novel small-molecule inhibitors of Wnt-dependent transcription. Cancer Res (2010) 2.05
Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate. J Med Chem (2010) 2.04